Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-005913-40-IT
EUCTR2005-005913-40-IT
Active, not recruiting
Not Applicable

A phase II, multicentre, clinical study evaluating the safety and efficacy of Treosulfan-based conditioning of allogenic transplantation of haemopoietic stem-cells in patients affected by Thalassemia Major - ND

OSPEDALE POLICLINICO S. MATTEO0 sites10 target enrollmentMarch 15, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsTreosulfan

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
OSPEDALE POLICLINICO S. MATTEO
Enrollment
10
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 15, 2006
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
OSPEDALE POLICLINICO S. MATTEO

Eligibility Criteria

Inclusion Criteria

  • •\- patients affected by Thalassemia Major \- age 1\-30 years old, etc...
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) no
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\- not provided written voluntary informed consent by parents \-hepatic desease, etc...

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular Carcinoma
CTIS2023-505698-34-00Merck Sharp & Dohme LLC102
Active, not recruiting
Phase 1
Phase 2 Study of MK 1308A (Coformulated MK 1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaAdvanced hepatocellular carcinoma without any prior systemic treatmentMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-004490-52-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.110
Active, not recruiting
Phase 2
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaAdvanced hepatocellular carcinoma
JPRN-jRCT2061210033Hoki Toshifumi6
Active, not recruiting
Phase 1
Phase 2 Study of MK 1308A (Coformulated MK 1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular Carcinoma
EUCTR2020-004490-52-PLMerck Sharp & Dohme LLC110
Active, not recruiting
Phase 1
A phase II, randomized, multi-center study, assessing value of adding RAD 001 to Trastuzumab as preoperative therapy of HER-2 positive primary breast cancer amenable to surgery - RADHER
EUCTR2007-004098-24-FRFNCLCC82